Anna Bogstedt

1.4k total citations
21 papers, 1.1k citations indexed

About

Anna Bogstedt is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Anna Bogstedt has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Physiology, 6 papers in Molecular Biology and 5 papers in Psychiatry and Mental health. Recurrent topics in Anna Bogstedt's work include Alzheimer's disease research and treatments (13 papers), Drug Transport and Resistance Mechanisms (4 papers) and Dementia and Cognitive Impairment Research (4 papers). Anna Bogstedt is often cited by papers focused on Alzheimer's disease research and treatments (13 papers), Drug Transport and Resistance Mechanisms (4 papers) and Dementia and Cognitive Impairment Research (4 papers). Anna Bogstedt collaborates with scholars based in Sweden, United Kingdom and United States. Anna Bogstedt's co-authors include Peter Annas, Hans Basun, Harald Hampel, Michael Ewers, Thomas Gasser, Thomas Leyhe, Lutz Frölich, Peter Schönknecht, Matthias W. Riepe and Anette Mörtberg and has published in prestigious journals such as Gastroenterology, Brain and Cardiovascular Research.

In The Last Decade

Anna Bogstedt

21 papers receiving 1.0k citations

Peers

Anna Bogstedt
Bernard‐François Michel France
Thomas J. Esparza United States
José Luna‐Muñoz Mexico
Tommy Saing United States
Eva Bagyinszky South Korea
Smirnov Av Germany
Jesús Aldudo Spain
Chica Mori United States
Marı́a Recuero Spain
Peter Filipčík Slovakia
Bernard‐François Michel France
Anna Bogstedt
Citations per year, relative to Anna Bogstedt Anna Bogstedt (= 1×) peers Bernard‐François Michel

Countries citing papers authored by Anna Bogstedt

Since Specialization
Citations

This map shows the geographic impact of Anna Bogstedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Bogstedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Bogstedt more than expected).

Fields of papers citing papers by Anna Bogstedt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Bogstedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Bogstedt. The network helps show where Anna Bogstedt may publish in the future.

Co-authorship network of co-authors of Anna Bogstedt

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Bogstedt. A scholar is included among the top collaborators of Anna Bogstedt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Bogstedt. Anna Bogstedt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davidsson, Pia, Susanna Eketjäll, Niclas Eriksson, et al.. (2023). Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease. Cardiovascular Research. 119(7). 1596–1605. 8 indexed citations
2.
Tóth, Miklós, Jenny Häggkvist, Anna Bogstedt, et al.. (2017). Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study. Journal of Alzheimer s Disease Reports. 1(1). 169–180. 15 indexed citations
3.
Billinton, Andy, Philip M. Newton, Chris J. Lloyd, et al.. (2017). [P1–074]: PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA‐AMYLOID 42 (Aβ42). Alzheimer s & Dementia. 13(7S_Part_5). 9 indexed citations
4.
Bereczki, Erika, Anna Bogstedt, Kina Höglund, et al.. (2017). Synaptic proteins in CSF relate to Parkinson’s disease stage markers. npj Parkinson s Disease. 3(1). 7–7. 57 indexed citations
5.
Eketjäll, Susanna, Juliette Janson, Anna Bogstedt, et al.. (2016). AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. Journal of Alzheimer s Disease. 50(4). 1109–1123. 97 indexed citations
6.
Bogstedt, Anna, Maria Groves, Keith Tan, et al.. (2015). Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. Journal of Alzheimer s Disease. 46(4). 1091–1101. 4 indexed citations
7.
Henderson, Simon J., Christin Andersson, Rajesh Narwal, et al.. (2013). Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. Brain. 137(2). 553–564. 72 indexed citations
8.
Haeberlein, Samantha Budd, Gvido Cebers, Kina Höglund, et al.. (2013). P4–296: AZD3293, a potent and selective orally active, brain‐permeable BACE1 inhibitor. Alzheimer s & Dementia. 9(4S_Part_20). 3 indexed citations
9.
Parkinson, Joanna, et al.. (2013). Modeling of age‐dependent amyloid accumulation and γ‐secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition. Pharmacology Research & Perspectives. 1(2). e00012–e00012. 5 indexed citations
10.
Wang, Fuhua, Tomas Klason, Olof Gissberg, et al.. (2012). Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma‐secretase inhibitor MRK‐560 as detected by manganese‐enhanced MRI. European Journal of Neuroscience. 36(9). 3165–3172. 24 indexed citations
11.
Höglund, Kina, Anna Bogstedt, Peter Annas, et al.. (2012). Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Plasma from Patients with Alzheimer's Disease. Journal of Alzheimer s Disease. 32(4). 939–947. 10 indexed citations
12.
13.
Hampel, Harald, Michael Ewers, Katharina Bürger, et al.. (2009). Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.. PubMed. 70(6). 922–31. 252 indexed citations
14.
Hampel, Harald, Michael Ewers, Katharina Bürger, et al.. (2009). Lithium Trial in Alzheimer's Disease. The Journal of Clinical Psychiatry. 70(6). 922–931. 231 indexed citations
15.
Hampel, Harald, Michael Ewers, Katharina Bürger, et al.. (2008). P4‐369: Lithium trial in Alzheimer's disease: A randomized, single‐blinded, placebo‐controlled, parallel group multicentre 10‐week study. Alzheimer s & Dementia. 4(4S_Part_24). 5 indexed citations
16.
Berndtson, E., et al.. (1997). Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni-infected chickens. Clinical & Experimental Immunology. 108(3). 451–455. 59 indexed citations
17.
Hammarström, Lennart, et al.. (1996). Oral IgA‐IgG treatment of chronic non‐specific diarrhoea in infants and children. Acta Paediatrica. 85(9). 1126–1128. 15 indexed citations
18.
Bogstedt, Anna, Silvia Nava, Torkel Wadström, & Lennart Hammarström. (1996). Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clinical & Experimental Immunology. 105(2). 202–204. 49 indexed citations
19.
Bogstedt, Anna, C. E. Nord, & Lennart Hammarström. (1995). Lack of effect of orally administered human serum immunoglobulin on the normal human oral and intestinal microflora. European Journal of Clinical Microbiology & Infectious Diseases. 14(1). 61–64. 5 indexed citations
20.
Casswall, Thomas, et al.. (1995). Oral IgA treatment of chronic non-specific diarrhoea in infants and children. Gastroenterology. 108(4). A792–A792. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernard‐François Michel Breakdown of academic impact, for papers by Thomas J. Esparza Breakdown of academic impact, for papers by José Luna‐Muñoz Breakdown of academic impact, for papers by Tommy Saing Breakdown of academic impact, for papers by Eva Bagyinszky Breakdown of academic impact, for papers by Smirnov Av Breakdown of academic impact, for papers by Jesús Aldudo Breakdown of academic impact, for papers by Chica Mori Breakdown of academic impact, for papers by Marı́a Recuero Breakdown of academic impact, for papers by Peter Filipčík
Rankless by CCL
2026